Some of the world’s top researchers in the promising field of cancer immunotherapy are gathering in New York this week at the Second International Cancer Immunotherapy Conference, hosted by the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR). This year’s theme, “Translating Science into Survival,” illustrates immunotherapy’s potential to save lives.
In a blog posted today on medium.com, Jill O’Donnell-Tormey, PhD, CEO and director of scientific affairs of CRI; and Elizabeth M. Jaffee, MD, deputy director at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, associate director of Bloomberg-Kimmel Institute for Cancer Immunotherapy, and member of the AACR Board of Directors (2013–2016), shared their thoughts about the exciting research discussed at the conference, and the challenges and the future of cancer immunotherapy. The full blog is posted here.
You may also like: